Gedea Biotech wins the "Rapidus company of the year" award
PRESS RELEASE
Gedea Biotech has been awarded the prestigious award "Rapidus Company of the Year". The ceremony…
Gedea Biotech has completed the recruitment for NEFERTITI clinical trial of pHyph antibiotic-free treatment of bacterial vaginosis
PRESS RELEASE Lund, Sweden, February 08, 2022. Swedish women’s health company Gedea Biotech today announced that despite the COVID-19 pandemic it has successfully completed recruitment of patients in the NEFERTITI clinical study of its lead product, pHyph, a vaginal tablet for topical treatment of…
Gedea Biotech - Top 20 European Biotech Companies to Watch in 2022
Labiotech.eu is the leading online media for the biotech industry in Europe. Gedea Biotech is the only Swedish company on Labiotech's annual list "The 20 European Biotech Companies to Watch in 2022". Labiotech has run articles about Gedea several times, focusing on our ambition to develop a…
Gedea receives funding for microbiome research project with Centre for Translational Microbiome Research at Karolinska Institutet
PRESS RELEASE Lund, Sweden, December 21, 2021. Swedish women’s health company Gedea Biotech today announced that it has received funding for a research project with the Centre for Translational Microbiome Research at Karolinska Institutet (KI), for its lead product, pHyph, a vaginal tablet for…
New Chairman of the board
Lund December 1, 2021. Femtech start-up Biotech today announces that Ton Berkien has been elected Chairman of the Board of Directors of…
Gedea Biotech granted European Patent for its treatment pHyph for women with vaginal fungal infections
PRESS RELEASE Lund, Sweden, October 25, 2021. Patent now valid in two of the world’s largest markets, Europe and USA until 2037 Swedish women’s health company Gedea Biotech today announced that the company has been granted a patent from the European Patent Office, covering the treatment of fungal…
Half way into Gedea Biotech’s NEFERTITI clinical trial of pHyph antibiotic-free treatment of bacterial vaginosis
Lund, Sweden, September 8, 2021, 2021. Swedish women’s health company Gedea Biotech today announced that it has enrolled more than 50% of patients in the NEFERTITI…
Gedea Biotech granted US patent for its antibiotic-free treatment pHyph for women with vaginal fungal infections
Lund, Sweden, August 31, 2021. Swedish women’s health company Gedea Biotech today announced that it has been granted a patent (US 10,993,907) by the United States Patent and Trademark Office (USPTO) for thetreatment of fungal infections by the company’s compound glucono-δ-lactone (GDL). The patent…
Progress in the clinical trial for bacterial vaginosis
Now, 57 patients, patients have been enrolled in the NEFERTITI clinical trial. Thanks to persistent and inventive investigators, in Sweden and in…
Deltagare söks till NEFERTITI-studien
30 mars 2021 Bakteriell vaginos, den vanligaste orsaken till besvärande flytningar från underlivet hos kvinnor uppstår på grund av tillväxt av bakterier som ger en obalans av de naturligt förekommande bakterierna i vaginan. Tillståndet drabbar hundratusentals svenska kvinnor varje år och det…